Brief: Transgene: First Head & Neck Cancer Patient Treated In France In Phase I Trial With TG4050

Transgene SA

21/01/2021 06:43

Jan 21 (Reuters) - TRANSGENE SA  TRNG.PA :
    * FIRST HEAD & NECK CANCER PATIENT TREATED IN FRANCE IN A
PHASE I
TRIAL WITH TG4050 (MYVAC® PLATFORM), TRANSGENE’S INNOVATIVE
INDIVIDUALIZED IMMUNOTHERAPY
    * COMBINES TRANSGENE'S EXPERTISE IN VIRUS-BASED
IMMUNOTHERAPIES,
NEC'S LONGSTANDING AI TECHNOLOGIES AND COMMITMENT OF PRESTIGIOUS
CANCER CARE CENTERS
    * FIRST DATA FROM TWO TRIALS EVALUATING TG4050 ARE EXPECTED
IN 2H
2021

Source text for Eikon:  ID:nBwb2g3zCa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))